HRP20200983T1 - Derivati nukleozid fosforamidata kao sredstva protiv raka - Google Patents
Derivati nukleozid fosforamidata kao sredstva protiv raka Download PDFInfo
- Publication number
- HRP20200983T1 HRP20200983T1 HRP20200983TT HRP20200983T HRP20200983T1 HR P20200983 T1 HRP20200983 T1 HR P20200983T1 HR P20200983T T HRP20200983T T HR P20200983TT HR P20200983 T HRP20200983 T HR P20200983T HR P20200983 T1 HRP20200983 T1 HR P20200983T1
- Authority
- HR
- Croatia
- Prior art keywords
- phenyl
- deoxyadenosine
- chloro
- phosphate
- cancer
- Prior art date
Links
- -1 Phosphoramidate nucleoside derivatives Chemical class 0.000 title claims 2
- 239000002246 antineoplastic agent Substances 0.000 title 1
- UENGBOCGGKLVJJ-UHFFFAOYSA-N 2-chloro-1-(2,4-difluorophenyl)ethanone Chemical compound FC1=CC=C(C(=O)CCl)C(F)=C1 UENGBOCGGKLVJJ-UHFFFAOYSA-N 0.000 claims 19
- 229910019142 PO4 Inorganic materials 0.000 claims 19
- 239000010452 phosphate Substances 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 17
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 3
- 125000006686 (C1-C24) alkyl group Chemical group 0.000 claims 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 201000004462 Leydig Cell Tumor Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 241000204031 Mycoplasma Species 0.000 claims 1
- 101150073096 NRAS gene Proteins 0.000 claims 1
- 229910003827 NRaRb Inorganic materials 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 241000036848 Porzana carolina Species 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 150000001336 alkenes Chemical class 0.000 claims 1
- 150000001345 alkine derivatives Chemical class 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Claims (15)
1. Spoj formule (I) ili njegova farmaceutski prihvatljiva sol:
[image]
R1 je aril;
R2 je odabran između C1-C24-alkila, C3-C24-alkenila, C3-C24-alkinil, C0-C4-alkilen-C3-C7-cikloalkila ili C0-C4-alkilen-arila;
R3 i R4 su svaki neovisno odabrani od H, C1-C6-alkila i C1-C3-alkilen-R9; ili pri čemu R3 i R4 zajedno s atomom na koji su vezani tvore 3- do 6-eročlanu cikloalkilnu ili heterocikloalkilnu grupu;
R5 i R7 su svaki neovisno odabrani od H i C1-C4-alkila;
R6 je neovisno odabran od H i C (O) R10;
R8 je neovisno odabran od H, C (O) OR10 i C (O) R10;
R9 je neovisno odabran između arila (npr. fenila), imidazola, indola, SRa, ORa, CO2Ra, CO2NRaRa, NRaRb i NH (= NH) NH2;
R10 je neovisno o svakoj pojavi odabran između C1-C24-alkila, C3-C24-alkenila, C3-C24-alkinil, C0-C4-alkilen-C3-C7-cikloalkil ili C0-C4-alkilen-aril;
pri čemu je svaka arilna skupina fenil, naftil ili tetrahidronaftil i pri čemu je bilo koja fenil, alkil, alkin, alkena, alkilen, cikloalkil, naftil ili tetrahidronaftil grupa izborno supstituirana s 1 do 4 supstituenta izabranih između: halo, nitro, cijano, NRaRa, NRaS(O)2Ra, NRaC(O)Ra, NRaCONRaRa, NRaCO2Ra, ORa; SRa, SORa, SO3Ra, SO2Ra, SO2NRaRa, CO2RaC(O)Ra, CONRaRa, CRaRaNRaRa, C1-C4-alkil, C2-C4-alkenil, C2-C4-alkinil i C1-C4-haloalkil;
pri čemu je Ra neovisno o svakoj pojavi odabran između: H i C1-C4-alkila; i Rb je neovisno o svakoj pojavi odabran između: H i C1-C4-alkila, C(O)-C1-C4-alkila, S(O)2-C1-C4-alkila.
2. Spoj prema zahtjevu 1, naznačen time što je spoj formule (I) spoj formule (II):
[image]
3. Spoj prema zahtjevu 1 ili zahtjevu 2, naznačen time što Rl je fenil; izborno pri čemu je R1 nesupstituirani fenil.
4. Spoj prema zahtjevu 1 ili zahtjevu 2, naznačen time što Rl je 1-naftil; izborno pri čemu je Rl nesupstituirani 1-naftil.
5. Spoj prema bilo kojem od zahtjeva 1 do 4, naznačen time što R2 je C4-C8-alkil; izborno pri čemu je R2 odabran između izo-butila, terc-butila, n-butila, n-pentila, CH2C(Me)3 ili n-heksila.
6. Spoj prema bilo kojem od zahtjeva 1 do 4, naznačen time što C5-C7-cikloalkil; izborno pri čemu je R2 nesupstituirani cikloheksil.
7. Spoj prema bilo kojem od zahtjeva 1 do 4, naznačen time što R2 je CHR11-fenil; pri čemu je R11 odabran od H i C1-C4-alkila; izborno gdje je R2 nesupstituirani benzil.
8. Spoj prema bilo kojem od zahtjeva 1 do 7, naznačen time što jedan od R3 i R4 je H i drugi je odabran od: H, Me, izopropil, izobutil i benzil izborno pri čemu R4 je H i R3 je odabran od: H, Me, izopropil , izobutil i benzil; dalje izborno gdje R4 je H i R3 je Me.
9. Spoj formule (I) u skladu s patentnim zahtjevom 1, izabran između:
2-kloro-2'-deoksiadenozin-3’ - [fenil- (etoksi-L-alaninil)] - fosfata,
2-kloro-2'-deoksiadenozin-3’ - [fenil- (terc-butoksi-L-alaninil)] - fosfata,
2-kloro-2'-deoksiadenozin-3’ - [fenil- (benzoksi-D-alaninil)] - fosfata,
2-kloro-2'-deoksiadenozin-3’ - [fenil- (benzoksi-glicinil)] - fosfata,
2-kloro-2'-deoksiadenozin-3’ - [fenil- (L-benzoksi-leucinska)] - fosfata,
2-kloro-2'-deoksiadenozin-3 '- [1-naftil- (2,2-dimetilpropoksi-L-alaninil)] fosfata,
2-kloro-2'-deoksiadenozin-3’ - [1-naftil- (pentoksi-L-leucinil)] - fosfata,
2-kloro-2'-deoksiadenozin-3’ - [1-naftil- (cikloheksoksi-L-alaninil)] - fosfata,
2-kloro-2'-deoksiadenozin-3’ - [fenil- (cikloheksoksi-L-alaninil)] - fosfata,
2-kloro-2'-deoksiadenozin-3’ - [fenil- (2,2-dimetilpropoksi-L-alaninil)] – fosfata,
2-kloro-2'-deoksiadenozin-3’ - [fenil- (etoksi-2,2-dimetilglicinil)] - fosfata,
2-kloro-2'-deoksiadenozin-3 '- [fenil- (benzoksi-L-fenilalaninil)] fosfata,
2-kloro-2'-deoksiadenozin-3 '- [1-naftil- (benzoksi-L-fenilalanil)] fosfata,
2-kloro-2'-deoksiadenozin-3 '- [fenil- (benzoksi-L-valinil)] fosfata,
2-kloro-2'-deoksiadenozin-3 '- [fenil (izo-propoksi-L-alaninil)] fosfata,
2-kloro-2'-deoksiadenozin-3 '- [fenil- (2-butoksi-L-alaninil)] fosfata,
2-kloro-2'-deoksiadenozin-3’ - [fenil - ((S) -1-feniletoksi-L-alaninil) fosfata,
2-kloro-2'-deoksiadenozin-3 '- [1-naftil- (benzoksi-L-alaninil) fosfata i
2-kloro-2'-deoksiadenozin-3’ - [fenil- (benzoksi-L-alaninil) fosfata.
10. Spoj prema bilo kojem od zahtjeva 1 do 9 za medicinsku uporabu.
11. Spoj prema bilo kojem od zahtjeva 1 do 9 za uporabu u liječenju raka.
12. Spoj za uporabu prema zahtjevu 11, naznačen time što je rak odabran iz grupe koja se sastoji od leukemije, multiplog mijeloma, raka pluća, raka jetre, raka dojke, raka glave i vrata, neuroblastoma, raka štitnjače, raka kože, raka oralnih pločastih stanica, raka mokraćnog mjehura, tumor Leydigovih stanica, raka debelog crijeva, kolorektalnog raka i ginekološkog raka.
13. Spoj za uporabu prema patentnom zahtjevu 11 ili zahtjevu 12, naznačen time što pacijent ima stanice zaražene mikoplazmom.
14. Spoj prema bilo kojem od zahtjeva 1 do 9 za uporabu u liječenju raka ciljanim matičnim stanicama raka.
15. Farmaceutska formulacija koja sadrži spoj prema bilo kojem od zahtjeva 1 do 9 i farmaceutski prihvatljiv ekscipijent.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1609601.8A GB201609601D0 (en) | 2016-06-01 | 2016-06-01 | Phosphoramidate compounds |
| PCT/GB2017/051549 WO2017207986A1 (en) | 2016-06-01 | 2017-05-31 | Phosphoramidate nucleoside derivatives as anticancer agents |
| EP17728596.2A EP3464309B1 (en) | 2016-06-01 | 2017-05-31 | Phosphoramidate nucleoside derivatives as anticancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200983T1 true HRP20200983T1 (hr) | 2020-12-11 |
Family
ID=56410850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200983TT HRP20200983T1 (hr) | 2016-06-01 | 2020-06-19 | Derivati nukleozid fosforamidata kao sredstva protiv raka |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10906929B2 (hr) |
| EP (1) | EP3464309B1 (hr) |
| JP (2) | JP7025351B2 (hr) |
| KR (1) | KR20190015353A (hr) |
| CN (1) | CN109195981A (hr) |
| AU (1) | AU2017273117B2 (hr) |
| BR (1) | BR112018074961A2 (hr) |
| CA (1) | CA3025440A1 (hr) |
| CL (1) | CL2018003404A1 (hr) |
| DK (1) | DK3464309T3 (hr) |
| EA (1) | EA036409B1 (hr) |
| ES (1) | ES2801448T3 (hr) |
| GB (1) | GB201609601D0 (hr) |
| HR (1) | HRP20200983T1 (hr) |
| HU (1) | HUE051335T2 (hr) |
| IL (1) | IL263121B (hr) |
| MX (1) | MX2018014859A (hr) |
| MY (1) | MY198880A (hr) |
| PH (1) | PH12018502606A1 (hr) |
| PL (1) | PL3464309T3 (hr) |
| PT (1) | PT3464309T (hr) |
| SA (1) | SA518400552B1 (hr) |
| SG (1) | SG11201810018TA (hr) |
| SI (1) | SI3464309T1 (hr) |
| WO (1) | WO2017207986A1 (hr) |
| ZA (1) | ZA201807652B (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| JP6646668B2 (ja) | 2014-11-28 | 2020-02-14 | ヌカナ ピーエルシー | 抗がん性化合物としての新規な２’および／または５’アミノ酸エステルホスホロアミダート３’−デオキシアデノシン誘導体 |
| EP3464271B1 (en) | 2016-05-31 | 2020-05-13 | Kalvista Pharmaceuticals Limited | Pyrazole derivatives as plasma kallikrein inhibitors |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| HRP20220367T1 (hr) | 2017-11-29 | 2022-05-27 | Kalvista Pharmaceuticals Limited | Oblici za doziranje koji sadrže plazmatski kalikrein inhibitor |
| GB201720279D0 (en) | 2017-12-05 | 2018-01-17 | Nucana Biomed Ltd | Anticancer compounds |
| WO2019172835A1 (en) * | 2018-03-09 | 2019-09-12 | Medivir Aktiebolag | Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides |
| EP4010333A1 (en) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| CN110845560B (zh) * | 2019-11-21 | 2021-08-24 | 广东中科药物研究有限公司 | 苯丙氨酸酰胺化的核苷酸衍生物及其制备方法与应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1309525A2 (en) * | 2000-07-13 | 2003-05-14 | Micrologix Biotech, Inc. | Synthesis and antiviral evaluation of nucleic acid based (nab) libraries |
| JP2008523082A (ja) | 2004-12-09 | 2008-07-03 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 抗菌活性および抗癌活性を有するヌクレオチド |
| GB0505781D0 (en) * | 2005-03-21 | 2005-04-27 | Univ Cardiff | Chemical compounds |
| BRPI1004575A2 (pt) | 2009-01-09 | 2016-04-05 | Inhibitex Inc | composto, composição farmacêutica, método de tratamento de infecções virais, método de separação dos diaestereômeros de fósforo |
| WO2012040126A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| US9156874B2 (en) * | 2011-01-03 | 2015-10-13 | Nanjing Molecular Research, Inc. | Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs |
| US8933053B2 (en) * | 2011-03-01 | 2015-01-13 | Nucana Biomed Limited | Phosphoramidate derivatives of 5-fluoro-2′-deoxyuridine for use in the treatment of cancer |
| US9156872B2 (en) | 2011-04-13 | 2015-10-13 | Merck Sharp & Dohme Corp. | 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| PL3043803T3 (pl) | 2013-09-11 | 2022-11-07 | Emory University | Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie |
| RU2016125213A (ru) | 2013-11-27 | 2017-12-29 | АЙДЕНИКС ФАРМАСЬЮТИКАЛЗ ЭлЭлСи | Нуклеотиды для лечения рака печени |
| WO2015181624A2 (en) * | 2014-05-28 | 2015-12-03 | Idenix Pharmaceuticals, Inc | Nucleoside derivatives for the treatment of cancer |
| PL3119794T3 (pl) | 2014-06-25 | 2018-04-30 | NuCana plc | Preparat zawierający prolek gemcytabiny |
| JP6646668B2 (ja) * | 2014-11-28 | 2020-02-14 | ヌカナ ピーエルシー | 抗がん性化合物としての新規な２’および／または５’アミノ酸エステルホスホロアミダート３’−デオキシアデノシン誘導体 |
| PT3307734T (pt) | 2015-06-09 | 2020-02-25 | Abbvie Inc | Moduladores de recetores nucleares (ror) para o tratamento de doenças inflamatórias e autoimunes |
| GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
| GB201609600D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
-
2016
- 2016-06-01 GB GBGB1609601.8A patent/GB201609601D0/en not_active Ceased
-
2017
- 2017-05-31 KR KR1020187037518A patent/KR20190015353A/ko active IP Right Grant
- 2017-05-31 US US16/305,153 patent/US10906929B2/en active Active
- 2017-05-31 AU AU2017273117A patent/AU2017273117B2/en active Active
- 2017-05-31 WO PCT/GB2017/051549 patent/WO2017207986A1/en unknown
- 2017-05-31 SI SI201730308T patent/SI3464309T1/sl unknown
- 2017-05-31 SG SG11201810018TA patent/SG11201810018TA/en unknown
- 2017-05-31 HU HUE17728596A patent/HUE051335T2/hu unknown
- 2017-05-31 PL PL17728596T patent/PL3464309T3/pl unknown
- 2017-05-31 EA EA201892745A patent/EA036409B1/ru unknown
- 2017-05-31 DK DK17728596.2T patent/DK3464309T3/da active
- 2017-05-31 CN CN201780033787.3A patent/CN109195981A/zh active Pending
- 2017-05-31 MX MX2018014859A patent/MX2018014859A/es unknown
- 2017-05-31 JP JP2018563085A patent/JP7025351B2/ja active Active
- 2017-05-31 MY MYPI2018002148A patent/MY198880A/en unknown
- 2017-05-31 ES ES17728596T patent/ES2801448T3/es active Active
- 2017-05-31 PT PT177285962T patent/PT3464309T/pt unknown
- 2017-05-31 EP EP17728596.2A patent/EP3464309B1/en active Active
- 2017-05-31 BR BR112018074961-3A patent/BR112018074961A2/pt not_active Application Discontinuation
- 2017-05-31 CA CA3025440A patent/CA3025440A1/en active Pending
-
2018
- 2018-11-14 ZA ZA2018/07652A patent/ZA201807652B/en unknown
- 2018-11-19 IL IL263121A patent/IL263121B/en unknown
- 2018-11-26 PH PH12018502606A patent/PH12018502606A1/en unknown
- 2018-11-29 SA SA518400552A patent/SA518400552B1/ar unknown
- 2018-11-29 CL CL2018003404A patent/CL2018003404A1/es unknown
-
2020
- 2020-06-19 HR HRP20200983TT patent/HRP20200983T1/hr unknown
-
2021
- 2021-01-06 US US17/142,936 patent/US20210130387A1/en not_active Abandoned
-
2022
- 2022-02-10 JP JP2022019417A patent/JP2022051936A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200983T1 (hr) | Derivati nukleozid fosforamidata kao sredstva protiv raka | |
| HRP20192209T1 (hr) | Derivati benzofurana, postupci njihove pripreme i njihova uporaba u medicini | |
| CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
| CY1118739T1 (el) | Ενωσεις αμφι(φθoρoαλκυλ)-1,4-βενζoδιαζεπινoνης ως αναστολεις toy notch | |
| PH12020551305A1 (en) | Pharmaceutical Compounds | |
| AR120109A1 (es) | Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores | |
| MX2020013373A (es) | Compuestos de naftiridinona utiles como activadores de celulas t. | |
| MX2019000123A (es) | Derivados de 1,3-dihidroxi-fenilo utiles como inmunomoduladores. | |
| MX2021013472A (es) | Moduladores de thr-? y metodos de uso de estos. | |
| MX2020013817A (es) | Compuestos de naftiridinona sustituidos utiles como activadores de celulas t. | |
| HRP20220886T1 (hr) | Pripravci i postupci za proizvodnju pirimidina i spojeva piridina s btk inhibicijskom aktivnošću | |
| MX2022007372A (es) | Compuestos de heteroarilo sustituidos utiles como activadores de celulas t. | |
| EA201891229A1 (ru) | Eif4a-ингибирующие соединения и связанные с ними способы | |
| CY1118572T1 (el) | Παραγωγο κυκλοαλκανιου | |
| MX2018009944A (es) | Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbon il-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a- tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico. | |
| JP2008513485A5 (hr) | ||
| MX2022006958A (es) | Compuestos de quinazolinilo sustituidos utiles como activadores de celulas t. | |
| AR116283A1 (es) | Inhibidores del sarcómero cardíaco | |
| RU2014115847A (ru) | Пирролопиримидиновые соединения для лечения злокачественной опухоли | |
| PE20211548A1 (es) | Compuesto de triazina y su uso para fines medicos | |
| CY1124970T1 (el) | Παραγωγα συγχωνευμενων δακτυλιων πυραζολιου και μεθοδος παρασκευης αυτων και εφαρμογη αυτων σε αντιμετωπιση καρκινων, φλεγμονης και νοσων του ανοσοποιητικου | |
| JP2017517565A5 (hr) | ||
| CL2021001396A1 (es) | Derivados de panteteína y usos de los mismos | |
| CY1120836T1 (el) | Ενωσεις 1,3,4-θειαδιαζοαης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| JP2018527301A5 (ja) | アジリジン含有ｄｎａアルキル化剤 |